Compare VIR & ASTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | ASTE |
|---|---|---|
| Founded | 2016 | 1972 |
| Country | United States | United States |
| Employees | N/A | 4468 |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2019 | 2003 |
| Metric | VIR | ASTE |
|---|---|---|
| Price | $10.03 | $61.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $19.43 | ★ $66.00 |
| AVG Volume (30 Days) | ★ 2.1M | 174.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.85% |
| EPS Growth | 17.49 | ★ 784.21 |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $68,556,000.00 | N/A |
| Revenue This Year | $270.22 | $14.72 |
| Revenue Next Year | N/A | $5.44 |
| P/E Ratio | ★ N/A | $1,029.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $37.83 |
| 52 Week High | $11.66 | $65.69 |
| Indicator | VIR | ASTE |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 66.19 |
| Support Level | $8.40 | $47.67 |
| Resistance Level | $10.10 | $61.22 |
| Average True Range (ATR) | 0.49 | 2.30 |
| MACD | 0.17 | 1.19 |
| Stochastic Oscillator | 79.78 | 79.52 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.